I-labeled
I-VT2. From this study, we conclude that Gb 3 binding is responsible for target organ localization of VT1 and disease production in the rabbit. The ability of Phe30Ala to induce both strong antibody and protective responses against VT1 suggests that VT mutants with reduced receptor binding properties may be useful in vaccine strategies. A further reduction in the toxicity of Phe30Ala would be required for its use as a natural toxoid to protect against human verotoxigenic E. coli infections.
Verotoxigenic Escherichia coli (VTEC) are associated with sporadic cases and outbreaks of both hemorrhagic colitis (14, 22) and the hemolytic-uremic syndrome (8, 9) . The virulence of these strains is determined to a large extent by the production of potent cytotoxins termed Shiga-like toxins or verotoxins (VTs) (27) . The verotoxins (VT1, VT2, and VT2c) are A:B 5 subunit toxins that are structurally related yet antigenically distinct (4, 15, 25) . The B subunit (35 kDa) is a pentamer (25) , responsible for the binding of the toxin to its eukaryotic globoseries glycosphingolipid receptor globotriaosylceramide (Gb 3 ) (11, 31) . The enzymatically active A subunit (32 kDa) inhibits eukaryotic protein synthesis by catalytically inactivating the 60S ribosomal subunit (3) .
Several animal models, including the mouse (32), pig (13) , dog (7) , and rabbit (20, 24, 33) , have been used to study the clinicopathologic effects of the verotoxins. Following intravenously (i.v.) administered injections of purified VT1, the rabbit has been shown to develop nonbloody diarrhea and progressive flaccid paralysis (20, 33) . These clinical features are hypothesized to be a result of binding of the toxin to Gb 3 receptors in the microvasculature of the gastrointestinal tract and central nervous system (CNS), with subsequent endothelial cell injury and microvascular thrombosis in the affected organs. These features are preventable by inducing immunity to VT1 (20) . The vascular lesions observed in the rabbit following i.v. VT1 administration are similar to those observed in the kidneys and other organs of hemolytic-uremic syndrome patients (20, 21) . Based on these studies, the pathological features of HUS are thought to be the result of toxin-mediated damage to the vascular endothelial cells of the renal glomeruli and other microvasculature via specific Gb 3 receptor binding. Thus, the rabbit appears to be a suitable model for studying the interaction of the VTs with endothelial cells in target blood vessels and for examining the efficacy of toxin-derived vaccines.
We have recently demonstrated that the substitution of alanine for phenylalanine 30 in the VT1 B subunit (Phe30Ala) resulted in a significant reduction in toxin binding to Gb 3 (2) . Furthermore, the cytotoxicity of Phe30Ala was reduced by 10 5 -fold compared with that of the wild-type toxin when examined on Vero cell monolayers (2) . The Phe30Ala B subunit was crystallized, and its crystal structure was found to be identical to that of the wild-type B subunit with the exception of the phenyl ring at position 30 (2) . We concluded that the dramatic reduction in in vitro cytotoxic activity by Phe30Ala was a result of the reduction in Gb 3 binding, due to the loss of the phenyl ring at position 30 and not to the disruption of the overall secondary structure of the molecule.
To better understand the role of Gb 3 receptor binding by the verotoxins in disease production, we examined the in vivo biological effects of Phe30Ala by comparing the results of the systemic administration of Phe30Ala and wild-type VT1 in rabbits. We hypothesized that Phe30Ala might be useful as a natural toxoid to protect against VT-mediated disease due to its retention of the secondary structure of the wild-type VT1 B subunit and its ability to associate with the A subunit. We therefore examined its efficacy and toxicity as a natural toxoid in rabbits.
(Presented in part at the 96th Annual Meeting of the American Society for Microbiology,-New Orleans, La., May 1996.)
MATERIALS AND METHODS
Bacterial strains. Plasmid pJLB128 encodes the wild-type VT1 holotoxin gene and was expressed in E. coli JM101 (19, 29) . Plasmid pJLB128(F30A) encodes the Phe30Ala holotoxin gene and was expressed in E. coli JM101 (2) .
Purification of VT1 and Phe30Ala holotoxins. By using polymyxin B (19), VT1 and Phe30Ala holotoxins were extracted from the periplasm of the overproducing E. coli strains described above. The holotoxins were purified by chromatography on hydroxylapatite (Bio-Rad, Richmond, Calif.), chromatofocusing (Pharmacia, Uppsala, Sweden), and affinity chromatography on a Cibachron blue column (Bio-Rad) as previously described (17) . The purity of the protein preparations was determined by reducing sodium dodecyl sulfate-polyacrylamide gel electrophoresis with 16% Tricene gels. The protein concentrations in purified samples were determined by the Pierce bicinchoninic acid protein assay (Pierce, Rockford, Illinois). All toxin preparations used in animal injections tested negative in the Limulus amoebocyte lysate assay (E-toxate; Sigma Chemical Co., St. Louis, Mo.) at a detection level of 0.05 to 0.1 endotoxin unit/ml.
Iodination of VT1 and Phe30Ala holotoxins. VT1, Phe30Ala, and VT2 holotoxins were radiolabelled with Na 125 I (Amersham)-and Iodogen (Pierce)-coated tubes as previously described (5) . The radiolabelled toxins were tested for Gb 3 binding by the microtitre plate assay (5) to ensure that labeling procedure had not altered the previously observed in vitro receptor binding pattern of all three toxins.
Intravenous administration of radiolabelled toxins. All procedures performed on animals were conducted in accordance with the principles put forth by the Animal Care Committee of the Hospital for Sick Children, Toronto, Canada. Saline suspensions of 125 I-VT1 and 125 I-Phe30Ala, at doses equivalent to 10 times the previously reported 50% lethal dose (LD 50 ) of VT1 (4 g) (20), were administered intravenously (i.v.) via the marginal ear vein to three and five New Zealand White male rabbits (2 kg each) (Reimens Fur Ranches), respectively. Samples of blood (1 ml) were taken from the artery of the ear at defined intervals immediately following injection. The total amount of circulating radiolabelled toxin in the blood was quantitated by monitoring for radioactivity on a Beckman gamma counter and multiplying the radioactivity per milliliter by the estimated total blood volume (55 ml/kg of body weight). The half-lives of both 125 I-VT1 and 125 I-Phe30Ala in serum were determined. At 2 h postchallenge, the level of radioactivity remaining in the bloodstream of 125 I-VT1-injected rabbits was 2% of that initially administered. These rabbits were then sacrificed by a lethal injection of 0.5 ml of pentobarbital (Euthanyl [240 mg/ml]; MTC Pharmaceuticals, Cambridge, Ontario, Canada) per kg. The five rabbits given injections of 125 I-Phe30Ala were sacrificed 10 h after the initial injection to allow the radioactivity in the bloodstream to reach 2% of the initial amount injected.
Following sacrifice, an autopsy was performed and individual organs were removed and analyzed for radioactivity. Samples (1 to 3 g) of the following tissues and organs were obtained: colon, cecum, small intestine, stomach, liver, skeletal muscle, heart, lung, kidney, spleen, spinal cord, and brain.
Clinicopathologic studies with Phe30Ala challenged rabbits. Five male New Zealand White rabbits (2.0 kg each) were challenged by i.v. injections of Phe30Ala holotoxin at a dose of 4 g/rabbit (equivalent to 10ϫ the LD 50 for VT1). Three control rabbits were challenged i.v. with wild-type VT1 at the same dose. All injections were administered via the marginal ear vein.
The rabbits were observed twice daily for evidence of the following symptoms and any other changes not observed in the control animals: ruffled fur, lethargy, decreased water and food consumption, mild to severe watery diarrhea with or without blood or mucus, and forelimb and/or hindlimb paralysis. The symptoms listed are those previously observed in a similar study conducted by Richardson et al. (20) .
Rabbits showing visible signs of severe clinical disease (diarrhea and/or limb paralysis) were sacrificed immediately by i.v. injection of 0.5 ml of pentobarbital per kg. Rabbits showing no signs of clinical disease were sacrificed by lethal injection of pentobarbitol 7 days postinjection. At autopsy the organs were examined for gross pathological abnormalities, and representative tissue specimens were taken from the brain, spinal cord, and cecum, as well as any other obviously involved organs. Tissues for histological examination were preserved in 10% buffered formalin immediately after removal. The same experiment was then performed at doses equivalent to 100 times the previously reported LD 50 of VT1 (40 g/rabbit).
Histopathologic analysis of tissue specimens. Formalin-preserved tissue specimens were embedded in paraffin and sectioned into 8-to 10-m-thick sections. All sections were stained with hematoxylin and eosin and examined by light microscopy. Each tissue section was examined by one observer who was unaware of the treatment status and clinical details. Abnormalities were scored on the basis of the presence or absence of edema, hemorrhage, infarction, and thrombotic vasculopathy on a scale of 0 to 3ϩ, representing absent, mild, moderate, and severe involvement, respectively, as previously described (20) . Scores for each of six target tissues (cecum, anterior brain, midbrain, cerebellum, cervical spinal cord, and lumbar spinal cord) were determined and a mean score per test animal calculated.
Immunization of rabbits with Phe30Ala and challenge with 125 I-VT1 and 125 I-VT2. Purified Phe30Ala was used to immunize six specific-pathogen-free New Zealand White rabbits. The rabbits were initially immunized with 4 g of Phe30Ala dissolved in 100 l of phosphate-buffered saline and emulsified with an equal volume of Freund's complete adjuvant (Sigma). On days 10 and 20 following the initial immunization, the rabbits were boosted with an additional 4 g of Phe30Ala dissolved in 100 l of phosphate-buffered saline and emulsified with an equal volume of Freund's incomplete adjuvant (Sigma). All immunizations were administered subcutaneously on the back of the animal. Sera were collected by a marginal ear vein bleed 14 days following the last immunization. Three rabbits were then challenged with 125 I-VT1, and three were challenged with 125 I-VT2, all at doses equivalent to 10 times the LD 50 of VT1.
ELISA and neutralization assays. Anti-VT1, anti-Phe30Ala, and anti-VT2 immunoglobulin G antibodies were assayed by a standard antibody enzymelinked immunosorbent assay (ELISA) optimized for use with VT1, Phe30Ala, and VT2 holotoxins as the coated test antigens (1a) . The ability of anti-Phe30Ala antisera to inhibit the cytotoxic effects of both VT1 and VT2 toward Vero cells was determined by an in vitro neutralization assay (9) . Serial twofold dilutions of antisera were preincubated with 0.003 ng of purified VT1 or VT2, which is 10 times the measured 50% cytotoxic dose. The serum neutralization titer was defined as the highest serial twofold dilution of serum at which 50% of the cells were killed by the effects of the toxin. Antibody titers were converted to logarithmic values [log 2 (x) and log 5 (x) for neutralizing and ELISA titers respectively, where x is the reciprocal of the serum dilution).
Statistical analysis. Standard errors of the mean were determined for all values in the figures. The one-tailed Student t test was used to determine significance. Statistical analyses were done with the functions contained within the Primer of Biostatistics (4a). (Fig. 1) . A mean half-life in serum of approximately 2 min was determined. I-Phe30Ala remaining in the bloodstream were 2 and 48%, respectively, of the initial amounts administered (Fig. 1) . All rabbits were sacrificed for localization studies when the level of radioactivity in the bloodstream was approximately 2% of the amount initially injected, so that the residual blood remaining in tissues would not interfere with the assessment of tissue localization, particularly for highly vascularized tissues. Rabbits that were given I-VT1 administered to immunologically naive New Zealand White rabbits was highly organ specific (Fig. 2a) I-VT1 accumulation. In contrast, those rabbits given injections of 125 I-Phe30Ala had markedly reduced accumulation in target organs. In particular, there was no sequestration of toxin in the gastrointestinal tract and CNS at 10 h postinjection (Fig. 2a) IPhe30Ala-treated rabbits were corrected for differences in organ blood flow by expressing the data in cpm per 100 g of tissue per specific organ blood flow (milliliters per minute per 100 g) (20) per total toxin dose (cpm) (Fig. 2b) . When the results were corrected for blood flow, the colon now had the largest accumulation of 125 I-VT1 followed by the cecum, spinal cord, small intestine, stomach, and brain. Again, the accumulation of 125 I-Phe30Ala was significantly lower than that of 125 I-VT1 in the colon, cecum, spinal cord, small intestine, and brain (PϽ0.01).
RESULTS

Elimination
Challenge with VT1 and Phe30Ala at doses equivalent to 10 times the LD 50 of VT1. The three control animals receiving VT1 holotoxin at a dose of 10 times the previously reported LD 50 of wild-type VT1 (20) exhibited the typical clinical features of VT1 intoxication at a mean of 17 h postchallenge; these included general malaise followed by severe paralysis and/or severe diarrhea. Histopathologic analysis showed all three rabbits to have evidence of VT effect, with mild to severe gastrointestinal tract and CNS involvement which was indistinguishable from that observed in previous studies with VT1 (20) . In the gastrointestinal tract, mucosal and submucosal edema, hemorrhage, and microvascular angiopathy were observed (Fig. 3B) . CNS lesions were characterized by focal hemorrhage and infarction, with thrombotic vasculopathy most prominent in the grey matter of the spinal cord (Fig. 4B ). Lesions were similar but more focal and less severe in the brain sections and more prominent in the cerebellum compared to anterior brain sections.
In contrast, the five rabbits challenged with Phe30Ala showed no clinical signs consistent with VT intoxication over a period of 7 days of observation. The gross pathologic findings were also normal. However, mild to moderate histopathologic abnormalities consistent with VT effect were observed in two rabbits, in the gastrointestinal tract (Fig. 3C) and CNS in one rabbit and in the CNS only (Fig. 4C) in the other. The other three rabbits showed minimal yet equivocal changes which may have been early VT effect or artifacts. The mean histopathologic score of the Phe30Ala-treated rabbits was significantly lower than that of the rabbits treated with VT1 (P Ͻ 0.05).
Challenge with VT1 and Phe30Ala at doses equivalent to 100 times the LD 50 of VT1. Clinical symptoms typical of VT effect were observed in all three rabbits challenged with Phe30Ala at a dose equivalent to 100 times the LD 50 of VT1; one had severe CNS symptoms, and two had moderate diarrhea without CNS symptoms. Typical symptoms also occurred in the wild-type-VT1-challenged control, although they occurred 7 h postchallenge as compared to 40 h in the Phe30Ala-challenged rabbits. At autopsy, mild cecal edema was evident in all three rabbits, although the cecal contents were adherent to the cecal mucosa as in unchallenged animals. Histopathologic testing showed that of the two rabbits with diarrhea, one had moder- ate histopathologic changes (Fig. 3D) while the other had mild or equivocal changes, as did the animal without diarrhea which had only CNS symptoms. CNS histopathologic testing showed severe involvement (Fig. 4D) in the affected rabbit and absent to mild involvement in the other two rabbits. The findings were typical of those observed in animals with VT1 intoxication in both the gastrointestinal tract and the CNS. The histopathologic score of the rabbits challenged with Phe30Ala at a dose equivalent to 100 times the LD 50 of VT1 was not significantly different from those challenged with wild-type VT1 at a dose of 10 times the LD 50 (P ϭ 0.498).
Tissue distribution of 125 I-VT1 and 125 I-VT2 in rabbits immunized with Phe30Ala. In contrast to the organ-specific localization of wild-type 125 I-VT1 in the gastrointestinal tract and CNS, its distribution in rabbits immunized against Phe30Ala was significantly different (Fig. 5) . The liver and spleen showed the greatest accumulation of 125 I-VT1, with negligible amounts measured in the gastrointestinal tract and CNS. The difference between the means of the uptake of radioactivity per milligram of tissue in immunologically naive and Phe30Ala immune rabbits was statistically significant for all tissues except the skeletal muscle, lung, heart, and kidney (P Ͻ 0.01). To examine the ability of Phe30Ala-raised antibodies to prevent specific tissue binding by the heterologous verotoxin VT2, both Phe30Ala immunized and immunologically naive rabbits were given i.v. injections of 125 I-VT2.
125
I-VT2 localized predominantly in the cecum, colon, and small intestine of rabbits not immunized with Phe30Ala (Fig. 6 ). Phe30Ala immune rabbits showed a partial reduction in the specific distribution of 125 I-VT2 in the cecum, colon, and small intestine. The difference between the means of the uptake of radioactivity per milligram of tissue in immunologically naive and Phe30Ala immune rabbits was statistically significant for only the colon and small intestine (P Ͻ 0.05) (Fig. 6) . Furthermore, a significant increase in the amount of 125 I-VT2 was noted in the liver (P Ͻ 0.05) but not the spleen of rabbits immunized with Phe30Ala.
Immunogenicity of the Phe30Ala holotoxin. Sera collected from Phe30Ala-immune rabbits immediately before the administration of radiolabelled toxins were subjected to titer determination for both cross-reactive and neutralizing antibodies to wild-type VT1, Phe30Ala, and VT2 holotoxins. When analyzed by ELISA, the reciprocal geometric mean titers of specific antibody to VT1, Phe30Ala, and VT2 were 8.15 (1:500,000), 8.15 (1:500,000), and 5.72 (1:10,000), respectively. Phe30Ala-raised antiserum also neutralized the toxic effects of VT1 in the in vitro Vero cell assay but was not able to neutralize the effects of VT2. The reciprocal geometric mean titer of neutralizing antibodies determined against 10 times the 50% cytotoxic dose of VT1 was 11.30 ϩ 0.35 (1:2519) (n ϭ 6).
DISCUSSION
The specific localization of i.v. administered VT1 to the gastrointestinal tract and CNS of the rabbit (20) correlates with the presence of Gb 3 in these tissues (33) . Furthermore, the localization of VT1 to endothelial cells of the gastrointestinal tract and CNS microvasculature correlates with the histologic changes observed in these tissues (20) . Based on these observations and the assumption that Gb 3 is present on microvascular endothelial cells of both tissues, it is hypothesized that the specific binding of VT1 to Gb 3 on vascular endothelium of the gastrointestinal tract and CNS of the rabbit leads to the vasculopathy observed in these tissues following i.v. VT1 challenge. To our knowledge, this study is the first direct in vivo demonstration that Gb 3 binding is responsible for target organ localization of VT1 and disease production in the rabbit.
A previously characterized VT1 B-subunit mutant (Phe30Ala) (2) was used in this study to better demonstrate the significance of Gb 3 receptor binding in disease production in the rabbit. The substitution of Ala for Phe30 in the VT1 B subunit caused a 4-fold reduction in Gb3 binding affinity and a 10-fold reduction in the number of receptors recognized (2) . This is consistent with the 52-fold-longer intravascular half-life and the significant reduction in target organ accumulation by 125 I-Phe30Ala compared to 125 I-VT1 in the rabbit in this study. This result strongly supports the hypothesis that Gb 3 receptor recognition and binding affinity play an important role in the intravascular clearance of VT1 and its accumulation in specific organs in the immunologically naive rabbit (20, 33) .
Although the accumulation in the target organs of observed in rabbits challenged with nonradiolabelled Phe30Ala at equivalent doses. However, the challenge of rabbits with Phe30Ala at 10-fold-higher doses (equivalent to 100ϫ the LD 50 of VT1) resulted in both clinical and pathologic effects indistinguishable from those in VT1-treated rabbits, although the onset of symptoms was delayed. This suggests that while a highly significant reduction in 125 I-Phe30Ala accumulation in target tissues and lack of clinical symptomatology was demonstrated at 10ϫ the LD 50 of VT1, at the higher dose (100ϫ the LD 50 of VT1) there was still enough residual binding to exert a significant biological effect.
The apparent 10-fold reduction in the biological effects in rabbits of Phe30Ala compared to wild-type VT1 is significantly less than the 10 5 -fold reduction in in vitro cytotoxicity on a Vero cell monolayer (2) . This most probably reflects the differences between the effect of the toxin on a cell monolayer and in a complex biological organ system in vivo. Several explanations may account for this discrepancy. It is conceivable that the residual binding by Phe30Ala induces host cytokine production. This in turn may sensitize the vascular endothelium to the effects of the toxin (26) by increasing the synthesis and membrane expression of Gb 3 , as has been previously demonstrated with wild-type VT1 in vitro (12, 18, 28, 30) . In recent studies, a correlation between the cytotoxic ability of Phe30Ala and the total Gb 3 concentration in various sensitive cell lines has been demonstrated. As the total Gb 3 content increases, so, too, does the ability of Phe30Ala to cause cell death (1). Second, Phe30Ala may bind preferentially to fatty acyl isotypes of Gb 3 which are not present in Vero cells but are present in the endothelium of the target microvascular beds of the gastrointestinal tract and CNS of the rabbit. Modifications in the fatty acid composition of the ceramide moiety of Gb 3 may alter the conformation or surface accessibility of the carbohydrate moiety necessary for toxin binding (10, 16, 23) . Binding of Phe30Ala to different Gb 3 isoforms may result in a distinct mechanism of endocytosis, intracellular routing, and translocation of the toxin necessary for cytotoxic action. Further studies are required to confirm both these hypotheses.
It has been shown that immunity to either VT1 or VT2 prevents the accumulation of both toxins in the gastrointestinal tract and CNS of rabbits (1b) despite the lack of cross-reactivity of anti-VT1 antisera against the cytotoxic effects of VT2 in the in vitro neutralization assay (1b, 6) . Thus, we proceeded to examine the efficacy of Phe30Ala as a natural toxoid in protecting against challenges with VT1 and VT2 in the rabbit model. The inhibition of accumulation of 125 I-VT1 in the gastrointestinal tract and CNS of Phe30Ala-immunized rabbits is consistent with the strong anti-VT1 IgG antibody response elicited in these animals, as measured by both ELISA and the VT1 neutralization assay. While no anti-VT2 in vitro neutralizing ability was detected, a partial inhibition of 125 I-VT2 accumulation in the gastrointestinal tract was demonstrated, which correlated with reduced anti-VT2 antibody ELISA titers (compared to anti-VT1 antibody ELISA titers). This may be due to the elimination of an important epitope in Phe30Ala that is necessary for VT2 clearance in vivo. While our study demonstrates that immunity to Phe30Ala reduces the accumulation of toxin in target tissues following an i.v. VT challenge, it is important to note that it does not measure biological protection. It is possible, though, that in a natural infection state where the toxin challenge would be much lower, immunity to Phe30Ala provides full protection against both VT1 and VT2 mediated disease.
This study provides the first direct in vivo observation that Gb 3 recognition and binding by VT1 are important for intravascular toxin clearance, organ targeting, and disease production in the rabbit. Furthermore, the results of this study demonstrate that VT mutants with reduced receptor binding, such as Phe30Ala, may provide sufficient immunity to protect against VT-associated diseases. However, despite its markedly reduced in vitro cytotoxicity, in vitro Gb 3 binding ability, and in vivo target organ accumulation, Phe30Ala is too toxic to be useful as a natural toxoid, especially for humans. The construction of VT1 mutant derivatives with additional B-subunit mutations may demonstrate acceptable toxicity profiles for use as natural human toxoids.
